Brief: Xspray Q2 Adj. EPS at SEK -2.27
02/08/2023 07:00
Aug 2 (Reuters) - Xspray Q2 adjusted EPS SEK -2.27. * Q2 adjusted free cash flow SEK -56.503 million * Q2 pretax profit SEK -51.402 million * Q2 revenue SEK 0
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003